Aurinia Pharmaceuticals Inc

Chart & Performance

D1W1MN

P/E

7.43

P/S

7.54

EPS

2.23

Div Yield, %

—

Shrs. gr., 5y

3.20%

Rev. gr., 5y

41.38%

Revenues

283m

+20.38%

Net income

287m

+4,893.08%

CFO

136m

+205.62%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and marketing medical treatments. The company focuses on addressing various diseases across the United States and China. A key part of its pipeline involves voclosporin, an investigational compound being developed to treat conditions such as lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's primary operations are based out of Victoria, Canada.

URL

https://www.auriniapharma.com

IPO date

Jul 16, 2001

Employees

300

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT